Vanguard Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDI
DTC
Vanguard Capital Management's CLDI Position: Q3 2026 in Review
Vanguard Capital Management increased its Calidi Biotherapeutics (CLDI) stake by 0.06% in Q3 2026, buying an estimated $2 and bringing the position to 1,595 shares worth $1.71K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.
Vanguard Capital Management first reported a position in CLDI in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.1K in Q1 2026. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2026.
- Vanguard Capital Management held 1,595 shares of Calidi Biotherapeutics worth $1.71K as of Q3 2026.
- Vanguard Capital Management bought 1 Calidi Biotherapeutics share in Q3 2026, an estimated $2.
- Calidi Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #4059 holding.
- Vanguard Capital Management first reported a position in Calidi Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Calidi Biotherapeutics position peaked at $6.1K in Q1 2026.
- 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.